In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor ...

Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant ...

When direct oral anticoagulants (DOACs) were developed, they were meant to entirely substitute vitamin K antagonists (VKAs) in the prevention of thromboembolism and stroke in patients with atrial ...

Atrial fibrillation is a cardiac arrhythmia in which the upper chambers of the heart the atria beat irregularly and, often, rapidly. The condition occurs as a consequence of uncoordinated ...

Attempt to get rid of the atrial fibrillation altogether and restore and maintain normal heart rhythm. Allow the atrial fibrillation to persist while controlling the heart rate There are different ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... cancer patients at risk of thrombosis in its MAGNOLIA and ...

Atrial fibrillation (AF) is the most commonly sustained arrhythmia and a significant ... were asked to answer additional AF-related questions on any history of thromboembolism, rheumatic heart disease ...

Atrial fibrillation (AF) is a common cardiac condition which increases the risk of stroke ... Major bleeds were defined as per the International Society of Thrombosis and Haemostasis,23 with the ...

AFib causes your heart to beat abnormally, which is a type of arrhythmia, but there are treatments that can help. Atrial fibrillation (AFib) is a problem with your heart's electrical activity.